• OPEN AN ACCOUNT
Indian Indices
Sensex
76,817.04 -447.47
( -0.58%)
Global Indices
Nasdaq
53,569.16 -21.28
(-0.04%)
Dow Jones
7,731.77 -20.22
(-0.26%)
Hang Seng
66,369.62 237.64
(0.36%)
Nikkei 225
10,816.31 23.77
(0.22%)
Forex
USD-INR
95.48 0.22
(0.23%)
EUR-INR
111.24 0.16
(0.15%)
GBP-INR
129.74 0.04
(0.03%)
JPY-INR
0.60 0.00
(0.12%)

EQUITY - MARKET SCREENER

Ajanta Pharma Ltd
Industry :  Pharmaceuticals - Indian - Formulations
BSE Code
ISIN Demat
Book Value()
532331
INE031B01049
337.9869392
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
AJANTPHARM
44.15
44472.92
EPS(TTM)
Face Value()
Div & Yield %
80.61
2
0.79
 

bcl enterprises ltd
Banco Products surges after Q4 PAT climbs 71% QoQ to Rs 147 cr
May 29,2026
Revenue from operations jumped 39.56% QoQ to Rs 1,091.10 crore in Q4 FY26.

On a year on year basis, the company’s consolidated net profit declined 3.95% while revenue from operations jumped 25.64% in Q4 FY26.

Profit before tax (PBT) fell 1.82% YoY to Rs 186.22 crore in Q4 FY26.

Total expenses climbed 32.56% to Rs 932.89 crore in Q4 FY26, compared with Rs 703.77 crore in Q4 FY25. Cost of material consumed stood at Rs 524.40 crore (down 11.23% YoY) and employee benefit expenses stood at Rs 126.05 crore (up 30.91% YoY) during the period under review.

On full year basis, the company’s consolidated net profit climbed 22.94% to Rs 481.68 crore in FY26, compared with Rs 391.80 crore posted in FY25. Revenue from operations increased 21.34% to Rs 3867.43 crore in FY26 compared with Rs 3187.24 crore in previous fiscal.

Meanwhile, the company’s board recommended final dividend of Rs 8 per equity share of face value Rs 2 each for the financial year 2025-26.

Banco Products (India) is engaged in the business of engine cooling and sealing systems both for automotive railway, and off-highway applications.